Lpl Financial LLC Outlook Therapeutics, Inc. Transaction History

Lpl Financial LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $22,000 - $66,000	100,000 Added 98.81%	201,200 $78,000
Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.26 $790 - $976	-775 Reduced 0.76%	101,200 $123,000
Q2 2022 Aug 12, 2022	BUY	$0.91 - $2.01 $45,955 - $101,504	50,500 Added 98.11%	101,975 $104,000
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $62,799 - $104,494	51,475 New	51,475 $92,000
Q4 2020 Feb 12, 2021	SELL	$0.7 - $1.58 $14,121 - $31,874	-20,174 Closed	0 $0

Q3 2020 Nov 09, 2020	BUY	$0.61 - $1.6 $1,647 - $4,320	2,700 Added 15.45%	20,174 $15,000
Q2 2020 Aug 13, 2020	BUY	$0.56 - $1.41 $3,751 - $9,445	6,699 Added 62.17%	17,474 $23,000
Q1 2020 May 14, 2020	BUY	$0.51 - $1.08 $5,495 - $11,637	10,775 New	10,775 $6,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.66B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.